Hunter Syndrome Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The hunter syndrome treatment market size is expected to grow from USD 1.38 billion in 2025 to USD 1.45 billion in 2026 and is forecast to reach USD 1.88 billion by 2031 at 5.24% CAGR over 2026-2031. This report is Segmented by Treatment Type (Enzyme Replacement Therapy (ERT), Hematopoietic Stem-Cell Transplant (HSCT), Gene & Other Advanced Therapies), End User (Hospitals, Diagnostic & Reference Laboratories, Home-Infusion & Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and More). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Global Hunter Syndrome Treatment Market Trends and Insights

Robust Orphan-Drug Incentives & Pricing Power

Orphan designations confer market exclusivity - seven years in the United States and ten years in Europe, allowing sponsors to recoup high R&D costs from an ultra-small patient base.In 2024, specialty-drug approvals represented more than 80% of all new U.S. medicines, underscoring the environment’s attractiveness to developers. Priority Review Vouchers deepen the appeal: Takeda’s hemophilia candidate ALHEMO secured one in December 2024, a transferrable asset that can shorten another drug’s regulatory review by four months. High list prices remain politically sensitive, but congressional proposals to soften Inflation Reduction Act provisions for sole orphan drugs signal continued legislative support. Consequently, pricing power is unlikely to erode materially over the 2025-2030 horizon, sustaining positive pressure on the Hunter syndrome treatment market.

Expanding Government Rare-Disease Funding Programs

Targeted grants stimulate discovery and translational science. The NIH PAR-25-266 call reserves resources for “high-value newborn-screen-eligible disorders,” explicitly citing mucopolysaccharidoses. Europe’s proposed Orphan Genomic Therapies Fund similarly seeks to balance innovation incentives with equitable access across member states. These programs enlarge pre-symptomatic patient pools, permitting earlier intervention and supporting volume growth in the Hunter syndrome treatment market. Medium-term impact is expected because funding cycles launch new studies within two to four years.

High Annual Therapy Cost & Reimbursement Friction

Chronic IV ERT regimens can top USD 400,000 annually, stretching public budgets and private insurers alike. Gene therapies priced as one-time cures intensify budget-impact concerns despite long-run cost offsets. Payers, therefore, impose stringent prior-authorization hurdles and often reimburse only when a a sustained neurological benefit is demonstrated, slowing uptake in the Hunter syndrome treatment market. Outcome-based payment models such as milestone reimbursements contingent on biomarker normalization - are emerging but remain inconsistently applied across jurisdictions.

Other drivers and restraints analyzed in the detailed report include:

• Commercial Launch of BBB-Penetrant ERTs
• Accelerating AAV9 & LV-Based Gene-Therapy Pipeline
• Limited CNS Efficacy of IV ERTs

Segment Analysis

Enzyme replacement therapy generated JPY 91.6 billion (USD 610 million) for Takeda in fiscal 2025, translating to an 81.35% Hunter syndrome treatment market share that year. Yet gene and other advanced modalities are growing at a 7.06% CAGR, setting the stage for material share shifts by 2031. Early RGX-121 recipients recorded stable adaptive behavior and motor development, prompting 80% to discontinue weekly ERT altogether. Hospitals and payers recognize the clinical and logistical advantages of a one-time infusion, supporting rapid adoption even at multimillion-dollar list prices.

Pipeline momentum is not limited to AAV9 vectors. Lentiviral autologous stem-cell therapy yielded supraphysiologic iduronate-2-sulfatase expression without conditioning-related neurotoxicity in early studies. Several firms are now evaluating base-editing and CRISPR platforms that could further reduce vector loads, although those candidates remain pre-IND. Manufacturing capacity is a gating factor: viral-vector clean rooms ran near full utilization in 2024-2025, delaying supply for compassionate-use requests. Even so, the Hunter syndrome treatment market size tied to advanced therapies is expected to climb swiftly once the first gene therapy secures global approvals, reinforcing the segment’s leadership in value creation.

Complete Report Scope:

• By Treatment Type
  • Enzyme Replacement Therapy (ERT)
  • Hematopoietic Stem-Cell Transplant (HSCT)
  • Gene & Other Advanced Therapies
• By End User
  • Hospitals
  • Diagnostic & Reference Laboratories
  • Home-Infusion & Specialty Clinics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led the Hunter syndrome treatment market with a 37.25% share in 2025, thanks to robust orphan-drug tax credits, FDA accelerated approval mechanisms, and broad commercial insurance coverage. Gene-therapy activity is mainly concentrated in the United States, where the FDA accepted cerebrospinal fluid heparan sulfate reduction as a surrogate for clinical benefit in pre-BLA meetings for RGX-121. The Inflation Reduction Act introduces uncertainty for long-term pricing, but current legislative drafts exempt sole-indication orphan drugs from Medicare negotiations, preserving headroom for premium pricing.

Europe offers streamlined centralized approval through the EMA, yet national reimbursement heterogeneity fragments access. Western European countries routinely reimburse high-cost orphan medicinal products within 12 months of marketing authorization, whereas Central and Eastern European markets often delay funding for two to three years. The proposed European Orphan Genomic Therapies Fund aims to bridge this gap by pooling risk and negotiating outcome-based contracts at an EU-wide level. Academic-industry consortia remain pivotal, with French, German, and UK centers running more than half of the active European clinical trials for Hunter syndrome gene therapy.

Asia Pacific is the fastest-growing region at an 8.08% CAGR through 2031, reflecting strengthening healthcare infrastructure and the proliferation of rare disease policies. Japan approved its first BBB-penetrant ERT in 2024 and signed accords to fast-track gene-therapy dossiers, driving regional interest from multinational sponsors. China expanded its National Rare Disease List to include mucopolysaccharidosis type II in 2025, unlocking provincial reimbursement pilots and boosting diagnostic rates. India rolled out state-level newborn screening programs that capture more than 40% of births, a significant leap from less than 10% coverage in 2023. Collectively, these reforms enlarge the patient pool and set the stage for sustained double-digit growth in the Hunter syndrome treatment market across Asia Pacific.

List of Companies Covered in this Report:

• Takeda Pharmaceuticals
• GC Biopharma
• JCR Pharmaceuticals Co. Ltd.
• REGENXBIO
• Denali Therapeutics
• Avrobio
• Sangamo Therapeutics
• Esteve Pharma
• Bioasis Technologies
• Clinigen Group
• CANbridge Life Sciences Ltd.
• ISU Abxis Co. Ltd.
• Ultragenyx Pharmaceutical
• Orchard Therapeutics plc
• Passage Bio Inc.
• uniQure N.V.
• Bluebird bio Inc.
• Idorsia Ltd.
• Lysogene S.A.
• ArmaGen Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support